We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Tells BMS to Correct GMP Issues Before Approving Biologic
FDA Tells BMS to Correct GMP Issues Before Approving Biologic
October 29, 2010
The FDA has told Bristol-Myers Squibb (BMS) that it will not approve the company’s BLA for transplant drug Nulojix (belatacept) until it resolves manufacturing issues at a Manati, Puerto Rico, facility.